Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 11/20 | 0.56 |
| ▸ | HTR2A | P28223 | 10/20 | 0.56 |
| ▸ | HTR2B | P41595 | 8/20 | 0.56 |
| ▸ | DRD1 | P21728 | 6/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | DRD5 | P21918 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | DRD2 | P14416 | 2/20 | 0.50 |
| ▸ | ADCY6 | O43306 | 1/20 | 0.50 |
| ▸ | ADCY3 | O60266 | 1/20 | 0.50 |
| ▸ | ADCY9 | O60503 | 1/20 | 0.50 |
| ▸ | ADCY5 | O95622 | 1/20 | 0.50 |
| ▸ | ADCY8 | P40145 | 1/20 | 0.50 |
| ▸ | ADCY7 | P51828 | 1/20 | 0.50 |
| ▸ | ADCY2 | Q08462 | 1/20 | 0.50 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.50 |
| ▸ | ADCY4 | Q8NFM4 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14282073 | 1.00 | HTR2C (0.56) | HTR2CHTR2AHTR2BDRD1KDM4E | |
| Hydrochloric Acid SCHEMBL4938389 | 0.99 | HTR2C (0.54) | HTR2CHTR2AHTR2BDRD1KDM4E | |
| Hydrochloric Acid SCHEMBL4929651 | 0.99 | HTR2C (0.54) | HTR2CHTR2AHTR2BDRD1KDM4E | |
| Hydrochloric Acid SCHEMBL4938393 | 0.99 | HTR2C (0.54) | HTR2CHTR2AHTR2BDRD1KDM4E | |
| SCHEMBL14282075 | 0.88 | HTR2C (0.53) | HTR2CHTR2AHTR2BDRD1DRD5 | |
| SCHEMBL4938100 | 0.88 | HTR2C (0.53) | HTR2CHTR2AHTR2BDRD1DRD5 | |
| SCHEMBL4939238 | 0.87 | HTR2C (0.56) | HTR2CHTR2AHTR2BADRA2C | |
| Hydrochloric Acid SCHEMBL4933482 | 0.87 | HTR2C (0.52) | HTR2CHTR2AHTR2BDRD1KDM4E | |
| Hydrochloric Acid SCHEMBL4933106 | 0.86 | HTR2C (0.54) | HTR2CHTR2AHTR2BADRA2C | |
| Hydrochloric Acid SCHEMBL4933105 | 0.86 | HTR2C (0.54) | HTR2CHTR2AHTR2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080009478-A1 | Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2c Receptor Associated Diseases | ARENA PHARMACEUTICALS, INC. (US) | 2008-01-10 | — | — | US | claimed |
| US-20210052600-A1 | THERAPEUTIC AGENTS FOR STRESS URINARY INCONTINENCE AND INCOTINENCE OF FECES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-02-25 | — | — | US | disclosed |
| EP-3733204-A1 | THERAPEUTIC AGENT FOR STRESS URINARY INCONTINENCE AND FECAL INCONTINENCE | Takeda Pharmaceutical Company Limited (JP) | 2020-11-04 | — | — | EP | disclosed |
| US-20150238506-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2015-08-27 | — | — | US | disclosed |
| US-20150238506-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2015-08-27 | — | — | US | disclosed |
| US-9079907-B2 | Fused heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-07-14 | — | — | US | disclosed |
| US-9079907-B2 | Fused heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-07-14 | — | — | US | disclosed |
| EP-2018863-B9 | Fused heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL (JP) | 2015-02-18 | — | — | EP | disclosed |
| EP-2789338-A2 | Condensed pyridine derivate and use thereof | Takeda Pharmaceutical Company Limited (JP) | 2014-10-15 | — | — | EP | disclosed |
| EP-2018863-B1 | Fused heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL (JP) | 2014-08-13 | — | — | EP | disclosed |
| US-20090131402-A1 | Fused heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-05-21 | — | — | US | disclosed |
| US-20090131402-A1 | Fused heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-05-21 | — | — | US | disclosed |
| EP-2018863-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2009-01-28 | — | — | EP | disclosed |
| US-20080009478-A1 | Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2c Receptor Associated Diseases | ARENA PHARMACEUTICALS, INC. (US) | 2008-01-10 | — | — | US | disclosed |
| US-20080009478-A1 | Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2c Receptor Associated Diseases | ARENA PHARMACEUTICALS, INC. (US) | 2008-01-10 | — | — | US | disclosed |
| US-20080009478-A1 | Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2c Receptor Associated Diseases | ARENA PHARMACEUTICALS, INC. (US) | 2008-01-10 | — | — | US | disclosed |
| US-20070274913-A1 | Preventives/Remedies for Stress Urinary Incontinence and Method of Screening the Same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-11-29 | — | — | US | disclosed |
| US-20070274913-A1 | Preventives/Remedies for Stress Urinary Incontinence and Method of Screening the Same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-11-29 | — | — | US | disclosed |
| EP-1792629-A1 | PREVENTIVES/REMEDIES FOR STRESS URINARY INCONTINENCE AND METHOD OF SCREENING THE SAME | Takeda Pharmaceutical Company Limited (JP) | 2007-06-06 | — | — | EP | disclosed |
| WO-2005042491-A1 | BENZAZEPINE DERIVATIVES AND METHODS OF PROPHYLAXIS OR TREATMENT OF 5HT2C RECEPTOR ASSOCIATED DISEASES | ARENA PHARMACEUTICALS, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131402-A1 | Fused heterocyclic compound and use thereof | HTR2C, HTR3C, HTR3B | HTR2C 1/4885HTR2A 4/4885HTR2B 5/4885 |
| US-20080009478-A1 | Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2c Receptor Associated Diseases | HTR2C, HTR2A, HTR2B | HTR2C 1/4885HTR2A 2/4885HTR2B 3/4885 |
| US-20070274913-A1 | Preventives/Remedies for Stress Urinary Incontinence and Method of Screening the Same | ADRA2C, HTR2C, HTR3A | HTR2C 2/4885HTR2A 5/4885HTR2B 15/4885 |
| US-20150238506-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | HTR2C, HTR3C, HTR3B | HTR2C 1/4885HTR2A 4/4885HTR2B 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.